Literature DB >> 22306682

Encapsulated papillary thyroid carcinoma: is it a distinctive clinical entity with low-grade malignancy?

A Pisanu1, D Deplano, I Reccia, G Porceddu, A Uccheddu.   

Abstract

BACKGROUND: Encapsulated papillary thyroid carcinoma (EPTC) is commonly retained as a tumor with indolent clinical courses. Herein we focused on the search for factors predicting biological behavior and influencing prognosis of EPTC in comparison with the non-encapsulated counterpart of papillary thyroid carcinoma (NEPTC).
METHODS: From January 1998 to May 2009, 348 patients underwent thyroidectomy in our surgical department because of papillary thyroid carcinoma (PTC). A cross-sectional study of 52 patients with EPTC and 296 patients with NEPTC was carried out: demographic data, tumor characteristics, diagnostic results, patient management, post-operative and follow-up results were evaluated.
RESULTS: EPTC patients were significantly younger than patients with NEPTC (44.5 vs 48.8 yr, p<0.04). Mean tumor size was significantly greater for EPTC than for NEPTC (2.36 vs 1.41 cm, p<0.001). Tumor multifocality, thyroid capsular invasion, and lymph node involvement at diagnosis were significantly associated with NEPTC (p=0.0001, p<0.0001, and p=0.027, respectively). Multivariate analyses showed that NEPTC classical variant were at risk for both thyroid capsular invasion and nodal involvement (odds ratio 6.870 and 9.514, respectively) while EPTC were not. Nodal metastasis at diagnosis was the only factor influencing recurrence.
CONCLUSIONS: The majority of EPTC had risk-free clinical courses as a result of their low risk of locoregional spread. However, definitive recommendations need a longer follow-up and a comparison with a lesser treated group of patients belonging to the same category of risk at diagnosis.

Entities:  

Mesh:

Year:  2012        PMID: 22306682     DOI: 10.3275/8241

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

Review 1.  Papillary neoplasms of the thyroid. Pathologic and prognostic features.

Authors:  V A LiVolsi
Journal:  Am J Clin Pathol       Date:  1992-03       Impact factor: 2.493

2.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Pacini; M G Castagna; L Brilli; G Pentheroudakis
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.

Authors:  Michael Rivera; Julio Ricarte-Filho; Jeff Knauf; Ashok Shaha; Michael Tuttle; James A Fagin; Ronald A Ghossein
Journal:  Mod Pathol       Date:  2010-06-04       Impact factor: 7.842

5.  Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases.

Authors:  Z W Baloch; V A LiVolsi
Journal:  Mod Pathol       Date:  2000-08       Impact factor: 7.842

6.  Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.

Authors:  Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

7.  Follicular variant of papillary thyroid carcinoma. A clinicopathologic study.

Authors:  E T Tielens; S I Sherman; R H Hruban; P W Ladenson
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

8.  The encapsulated papillary carcinoma of the thyroid. A morphologic subtype of the papillary thyroid carcinoma.

Authors:  S Schröder; W Böcker; H Dralle; K B Kortmann; C Stern
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

9.  Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).

Authors:  Michael Rivera; R Michael Tuttle; Snehal Patel; Ashok Shaha; Jatin P Shah; Ronald A Ghossein
Journal:  Thyroid       Date:  2009-02       Impact factor: 6.568

10.  Further evidence of the validity of risk group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi; M Silverman; M Wool
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

View more
  3 in total

1.  Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis.

Authors:  Chenghao Jiang; Tong Cheng; Xucai Zheng; Shikai Hong; Song Liu; Jianjun Liu; Jing Wang; Shengying Wang
Journal:  Cancer Manag Res       Date:  2018-03-09       Impact factor: 3.989

2.  Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus.

Authors:  Jian Li; Minghua Luo; Huiting Ou; Xiaoling Liu; Xueling Kang; Weihua Yin
Journal:  J Cancer       Date:  2019-10-21       Impact factor: 4.207

3.  Capsular Invasion Matters Also in "Papillary Patterned" Tumors: A Study on 121 Cases of Encapsulated Conventional Variant of Papillary Thyroid Carcinoma.

Authors:  Dilara Akbulut; Ezgi Dicle Kuz; Nazmiye Kursun; Serpil Dizbay Sak
Journal:  Endocr Pathol       Date:  2021-01-04       Impact factor: 3.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.